Polski Bank Komórek Macierzystych S.A. (Polish Stem Cell Bank JSC, PBKM), acting on the international market under the FamiCord Group brand, is a cord blood bank founded in 2002, that is involved in acquiring, collecting and long-term storing of the stem cells derived from the umbilical cord blood and the other afterbirth tissues on the commission of the parents within a frame of a so-called family banking. An objective of PBKM consists in ensuring safety for a family in case of an occurrence of a serious disease that requires a transplantation of the stem cells in a donor or the members of his/her immediate family.
FamiCord Group is the largest cord blood bank in Europe with around 30% of the market share, including the latest acquisitions in Portugal and Spain. At the end of the Q1 2019, the Group stored over 319 thousand of umbilical cord blood or tissues and over 428 thousand all biological samples.
FamiCord Group is present on several European markets. Directly offers services to clients in Poland, Turkey, Spain, Portugal, Hungary, Romania, Switzerland, Italy and Latvia. Almost everywhere is the number 1 on the market. In addition, it provides services for partners who acquire customers in Sweden, Denmark, Serbia and the Balkan countries, Italy and Ukraine. The Group's services are carried out through a network of own banks and cooperating banks located, among others, in Germany, USA and UK.
In addition, the Group invests in the development of advanced therapy medicinal products (ATMP) services, which are considered to be one of the most important directions of development in medicine. PBKM Group is currently involved in 5 clinical trials of phase II and II/III (ultimately there will be 8 clinical trials) stem cells therapies for various diseases.
Since May 2016 Polski Bank Komórek Macierzystych S.A. has been listed on the main market of the Warsaw Stock Exchange.
More information on the services rendered by PBKM can be found on the following website: www.pbkm.pl